Mario Riverol1, Andrea Slachevsky2, Oscar L López3. 1. Department of Neurology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA ; Department of Neurology, Clínica Universidad de Navarra, Pamplona, Spain. 2. Unidad de Neurología Cognitiva y Demencia, Servicio de Neurología, Hospital del Salvador. Facultad de Medicina Universidad de Chile, Santiago, Chile ; Servicio de Neurologia, Clínica Alemana, Santiago, Chile. 3. Department of Neurology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA ; Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Abstract
INTRODUCTION: Two types of drugs have been approved for the symptomatic treatment of Alzheimer's disease (AD): the cholinesterase inhibitors (ChEIs) and memantine. There is a growing interest to know whether the combination of these drugs is safe and if it adds any clinical benefit to patients. OBJECTIVE: To systematically review published medical literature assessing the efficacy and tolerability of a combination treatment of memantine and donepezil in AD patients. METHODS: We searched PubMed for English and Spanish-language literature, using the terms "Alzheimer's disease," "cholinesterase inhibitors," "donepezil," and "memantine." Our review focused on clinical trials and observational studies. RESULTS: Eleven publications representing seven unique studies were selected for this review. Three were randomized double-blind, placebo-controlled trials and four were observational studies. CONCLUSIONS: Available data revealed that the combination of memantine and donepezil slowed down cognitive decline, prolonged functional independence, and improved behavioral symptoms in patients with moderate to severe AD. The long-term use of the dual therapy decreased the risk of nursing home admission. More longitudinal studies are needed to further examine the role of combined therapy in the management of AD patients.
INTRODUCTION: Two types of drugs have been approved for the symptomatic treatment of Alzheimer's disease (AD): the cholinesterase inhibitors (ChEIs) and memantine. There is a growing interest to know whether the combination of these drugs is safe and if it adds any clinical benefit to patients. OBJECTIVE: To systematically review published medical literature assessing the efficacy and tolerability of a combination treatment of memantine and donepezil in ADpatients. METHODS: We searched PubMed for English and Spanish-language literature, using the terms "Alzheimer's disease," "cholinesterase inhibitors," "donepezil," and "memantine." Our review focused on clinical trials and observational studies. RESULTS: Eleven publications representing seven unique studies were selected for this review. Three were randomized double-blind, placebo-controlled trials and four were observational studies. CONCLUSIONS: Available data revealed that the combination of memantine and donepezil slowed down cognitive decline, prolonged functional independence, and improved behavioral symptoms in patients with moderate to severe AD. The long-term use of the dual therapy decreased the risk of nursing home admission. More longitudinal studies are needed to further examine the role of combined therapy in the management of ADpatients.
Authors: Cleusa P Ferri; Martin Prince; Carol Brayne; Henry Brodaty; Laura Fratiglioni; Mary Ganguli; Kathleen Hall; Kazuo Hasegawa; Hugh Hendrie; Yueqin Huang; Anthony Jorm; Colin Mathers; Paulo R Menezes; Elizabeth Rimmer; Marcia Scazufca Journal: Lancet Date: 2005-12-17 Impact factor: 79.321
Authors: O L Lopez; J T Becker; A S Wahed; J Saxton; R A Sweet; D A Wolk; W Klunk; S T Dekosky Journal: J Neurol Neurosurg Psychiatry Date: 2009-02-09 Impact factor: 10.154
Authors: C Holmes; D Wilkinson; C Dean; S Vethanayagam; S Olivieri; A Langley; N D Pandita-Gunawardena; F Hogg; C Clare; J Damms Journal: Neurology Date: 2004-07-27 Impact factor: 9.910
Authors: Annette L Fitzpatrick; Lewis H Kuller; Diane G Ives; Oscar L Lopez; William Jagust; John C S Breitner; Beverly Jones; Constantine Lyketsos; Corinne Dulberg Journal: J Am Geriatr Soc Date: 2004-02 Impact factor: 5.562
Authors: Christopher H van Dyck; Pierre N Tariot; Barnett Meyers; E Malca Resnick Journal: Alzheimer Dis Assoc Disord Date: 2007 Apr-Jun Impact factor: 2.703